Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cardiff Oncology, Inc. CRDF

Healthcare  —  Biotechnology
1.24 (0.04) (3.13%) as of 25 Sep
Market cap
$99.6M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Cardiff Oncology, Inc. (CRDF) Business Profile

Updated before January 2025

Company Overview

Cardiff Oncology, Inc. (NASDAQ: CRDF) is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. Founded in 1999 and headquartered in San Diego, California, Cardiff Oncology is dedicated to addressing unmet medical needs in oncology through the development of precision medicine. The company’s mission is to improve the lives of cancer patients by advancing targeted therapies that enhance treatment outcomes.

The company’s leadership team is composed of seasoned professionals with extensive experience in biotechnology and oncology research. Mark Erlander, Ph.D., serves as the Chief Executive Officer, bringing decades of expertise in molecular diagnostics and cancer biology. Cardiff Oncology’s board of directors and scientific advisory board include prominent figures in the biotech and pharmaceutical industries, ensuring strategic guidance and scientific rigor in its operations.

Core Business Segments

Cardiff Oncology’s primary focus is on the development of precision oncology therapeutics. The company’s flagship product candidate is onvansertib, an oral and highly selective Polo-like Kinase 1 (PLK1) inhibitor. Onvansertib is being evaluated in combination with standard-of-care therapies for the treatment of various cancers, including:

  • Colorectal Cancer (mCRC): Onvansertib is being studied in combination with FOLFIRI and bevacizumab for patients with KRAS-mutated metastatic colorectal cancer. This mutation is present in approximately 40% of colorectal cancer cases and is associated with poor prognosis.
  • Pancreatic Cancer: The company is exploring the potential of onvansertib in combination with standard chemotherapy regimens for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with limited treatment options.
  • Prostate Cancer: Onvansertib is also being investigated for metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone.

In addition to onvansertib, Cardiff Oncology is actively engaged in preclinical research to expand its pipeline of targeted therapies. The company’s approach leverages biomarker-driven strategies to identify patient populations most likely to benefit from its treatments.

Business Model

Cardiff Oncology operates as a clinical-stage biotechnology company, focusing on the research, development, and commercialization of targeted cancer therapies. The company’s business model is centered around:

  1. Research and Development (R&D): Cardiff Oncology invests heavily in R&D to advance its pipeline of precision oncology therapeutics. The company collaborates with leading academic institutions, research organizations, and clinical trial sites to accelerate the development of its drug candidates.
  2. Partnerships and Collaborations: Cardiff Oncology seeks strategic partnerships with pharmaceutical companies to co-develop and commercialize its therapies. These collaborations provide access to additional resources, expertise, and market reach.
  3. Revenue Generation: As a clinical-stage company, Cardiff Oncology does not yet generate revenue from product sales. Future revenue streams are expected to come from the commercialization of onvansertib and other pipeline candidates, as well as potential licensing agreements and milestone payments from partners.

Strategic Direction

Cardiff Oncology’s strategic priorities include:

  • Advancing Clinical Trials: The company is focused on progressing its ongoing clinical trials for onvansertib in colorectal, pancreatic, and prostate cancers. Positive trial results will pave the way for regulatory approvals and commercialization.
  • Expanding the Pipeline: Cardiff Oncology aims to broaden its portfolio by identifying new therapeutic targets and developing additional drug candidates. The company is particularly interested in leveraging biomarkers to guide drug development.
  • Global Market Expansion: Cardiff Oncology plans to establish a global presence by seeking regulatory approvals in key markets such as the United States, Europe, and Asia. The company is also exploring opportunities for international partnerships.
  • Sustainability Goals: While not a primary focus, Cardiff Oncology is committed to conducting its operations responsibly and minimizing its environmental impact.

Competitive Landscape

Cardiff Oncology operates in a highly competitive biotechnology sector, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Amgen: A leader in oncology with a strong portfolio of targeted therapies.
  • Bristol-Myers Squibb: Known for its immuno-oncology drugs, including checkpoint inhibitors.
  • Mirati Therapeutics: Focused on developing therapies targeting KRAS mutations, a key area of overlap with Cardiff Oncology.
  • Array BioPharma (acquired by Pfizer): Specializes in small-molecule drugs for cancer treatment.

Despite the competition, Cardiff Oncology differentiates itself through its focus on PLK1 inhibition and biomarker-driven approaches, which offer the potential for more personalized and effective cancer treatments.

Risk Factors

Cardiff Oncology faces several risks that could impact its business operations and financial performance:

  • Clinical Trial Risks: The success of the company’s drug candidates depends on the outcomes of clinical trials, which are inherently uncertain and time-consuming.
  • Regulatory Risks: Obtaining regulatory approvals for new drugs is a complex and rigorous process. Delays or failures in this process could hinder the company’s growth.
  • Market Dependence: As a clinical-stage company, Cardiff Oncology is heavily reliant on the success of onvansertib. Failure to commercialize this product could significantly impact its prospects.
  • Supply Chain Disruptions: The company depends on third-party manufacturers and suppliers for the production of its drug candidates. Disruptions in the supply chain could delay clinical trials and commercialization efforts.
  • Financial Risks: Cardiff Oncology is not yet profitable and relies on external funding to finance its operations. Limited access to capital could constrain its ability to execute its strategic plans.

Recent Developments

Cardiff Oncology has made significant progress in advancing its clinical programs and corporate strategy:

  • Clinical Trial Updates: The company recently announced positive interim results from its Phase 1b/2 trial of onvansertib in KRAS-mutated metastatic colorectal cancer. The data demonstrated improved progression-free survival and overall response rates.
  • Collaborations: Cardiff Oncology entered into a partnership with a leading academic institution to explore new applications for onvansertib in additional cancer types.
  • Corporate Strategy: The company strengthened its leadership team by appointing new executives with expertise in oncology drug development and commercialization.
  • Global Developments: The COVID-19 pandemic posed challenges for clinical trial enrollment and supply chain logistics. However, Cardiff Oncology successfully adapted its operations to mitigate these impacts.

Investment Considerations

Investors considering Cardiff Oncology should weigh the following factors:

Strengths:

  • Innovative Pipeline: Onvansertib has the potential to address significant unmet needs in oncology, particularly for KRAS-mutated cancers.
  • Biomarker-Driven Approach: The company’s focus on precision medicine increases the likelihood of clinical success and market adoption.
  • Experienced Leadership: Cardiff Oncology’s management team has a proven track record in oncology drug development.

Risks:

  • Early-Stage Company: As a clinical-stage biotech, Cardiff Oncology is not yet generating revenue and remains dependent on external funding.
  • Regulatory and Clinical Risks: The success of the company’s pipeline hinges on the outcomes of clinical trials and regulatory approvals.
  • Market Competition: The oncology sector is highly competitive, with numerous companies targeting similar indications.

Conclusion

Cardiff Oncology, Inc. is a promising player in the biotechnology sector, with a strong focus on precision oncology and biomarker-driven drug development. The company’s flagship product candidate, onvansertib, has shown encouraging results in clinical trials and has the potential to address significant unmet needs in cancer treatment. While Cardiff Oncology faces risks typical of early-stage biotech companies, its innovative pipeline, experienced leadership, and strategic focus position it well for future growth. Investors with a high-risk tolerance and a long-term perspective may find Cardiff Oncology to be an attractive opportunity in the oncology space.